Yu AL - Search Results

1

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial.

2

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF. Saleh MN, et al. Among authors: yu al. Hum Antibodies Hybridomas. 1992 Jan;3(1):19-24. Hum Antibodies Hybridomas. 1992. PMID: 1576319 Clinical Trial.

3

Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.

Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Barker E, et al. Among authors: yu al. Cancer Res. 1991 Jan 1;51(1):144-9. Cancer Res. 1991. PMID: 1988079

4

Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.

Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL. Uttenreuther-Fischer MM, et al. Among authors: yu al. Cancer Immunol Immunother. 1995 Jul;41(1):29-36. doi: 10.1007/BF01788957. Cancer Immunol Immunother. 1995. PMID: 7641217 Free PMC article. Clinical Trial.

5

Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy.

Reisfeld RA, Mueller BM, Handgretinger R, Yu AL, Gillies SD. Reisfeld RA, et al. Among authors: yu al. Prog Brain Res. 1994;101:201-12. Prog Brain Res. 1994. PMID: 8029452 Review. No abstract available.

6

Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody.

Xiao WH, Yu AL, Sorkin LS. Xiao WH, et al. Among authors: yu al. Pain. 1997 Jan;69(1-2):145-51. doi: 10.1016/s0304-3959(96)03280-0. Pain. 1997. PMID: 9060025

7

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH. Yu AL, et al. J Clin Oncol. 1998 Jun;16(6):2169-80. doi: 10.1200/JCO.1998.16.6.2169. J Clin Oncol. 1998. PMID: 9626218 Clinical Trial.

8

The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.

Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL. Batova A, et al. Among authors: yu al. Clin Cancer Res. 1999 Dec;5(12):4259-63. Clin Cancer Res. 1999. PMID: 10632368

9

p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.

Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL. Omura-Minamisawa M, et al. Among authors: yu al. Clin Cancer Res. 2001 Nov;7(11):3481-90. Clin Cancer Res. 2001. PMID: 11705866

10

Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.

Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW, Cohn SL. Kletzel M, et al. Among authors: yu al. J Clin Oncol. 2002 May 1;20(9):2284-92. doi: 10.1200/JCO.2002.06.060. J Clin Oncol. 2002. PMID: 11980999 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

300 results

Search Page